Anika Therapeutics, Inc. (ANIK) Financials

ANIK Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2026 189.6 million 52.0 million
June 30, 2026 183.5 million 46.2 million
March 31, 2026 179.4 million 45.5 million
Dec. 31, 2025 190.3 million 46.8 million

ANIK Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2026 6.7 million 4.2 million
June 30, 2026 -2.1 million 1.8 million
March 31, 2026 -6.3 million 6.6 million
Dec. 31, 2025 4.0 million 2.5 million

ANIK Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
Sept. 30, 2026 -311000
June 30, 2026 3.3 million
March 31, 2026 -5.1 million
Dec. 31, 2025 292000

ANIK Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2026 45.0 million 24.6 million 26.1 million
June 30, 2026 38.4 million 23.3 million 25.3 million
March 31, 2026 41.0 million - 23.8 million
Dec. 31, 2025 57.5 million 24.2 million 2.1 million

ANIK Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2026 13.4 million
June 30, 2026 13.4 million
March 31, 2026 13.5 million
Dec. 31, 2025 14.7 million

ANIK Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2026 1.7 million 7.9 million 11.7 million -
June 30, 2026 1.4 million 7.3 million 10.9 million -
March 31, 2026 1.4 million 6.7 million 17.8 million -
Dec. 31, 2025 648000 6.5 million 12.1 million -

ANIK Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2026 30.6 million 11.8 million
June 30, 2026 32.6 million 11.4 million
March 31, 2026 29.6 million 10.6 million
Dec. 31, 2025 30.6 million 11.4 million

ANIK Revenue by Segment

Graph available only for paid members. Upgrade to see it.

ANIK

Price: $13.40

52 week price:
9.01
22.88

Earnings Per Share: -0.03 USD

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 53407

Ebitda: 11.5 million

Market Capitalization: 185.0 million

Links: